The estrogenic activity of ginseng has been the subject of conflicting reports. Cell proliferation, induction of estrogen-responsive genes, and isolated cases of adverse reactions such as postmenopausal vaginal bleeding and gynecomastia have been reported after ginseng treatment. Other studies report antiproliferative effects with no induction of estrogen-responsive genes. We developed estrogen receptor (ER) α and ERβ competitive binding assays using recombinant receptors and [3H]-17β-estradiol to detect phytoestrogens in extracts of Asian ginseng root (Panax ginseng C. A. Meyer) and American ginseng root (Panax quinquefolius L.). Root extracts contained substances that bound both receptor isoforms. These substances had a two to three times greater affinity for ERβ. Significantly higher binding was found in methanol extracts than in hot water extracts. Subsequent analysis of the extracts revealed significant ER binding attributable to zearalenone, the estrogenic mycotoxin produced by several Fusarium species. The ER showed no binding affinity for Rb1 and Rg1, the major ginsenosides found in P. quinquefolius and P. ginseng, respectively. Thus, ginseng extraction methods, plant species tested, and mycotoxin contaminants may help to explain the disparate literature reports. The prevalence and health significance of fungal contamination in herbal products used for medicinal purposes should be further investigated.
AstinJA. Why patients use alternative medicine: results of a national study. JAMA279: 1548–1553, 1998.
2.
BonielT, DannonP. The safety of herbal medicines in the psychiatric practice (abstract). Harefuah140: 780–783, 2001.
3.
ErnstE. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med136: 42–53, 2002.
4.
ErnstE, CassilethBR. How useful are unconventional cancer treatments?Eur J Cancer35: 1608–1613, 1999.
5.
HarkeyMR, HendersonGL, GershwinME, SternJS, HackmanRM. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr73: 1101–1106, 2001.
6.
KittsD, HuC. Efficacy and safety of ginseng. Public Health Nutr3: 473–485, 2000.
7.
PribitkinED, BogerG. Herbal therapy: what every facial plastic surgeon must know. Arch Facial Plast Surg3: 127–132, 2001.
8.
BlumenthalM. Herbal Medicine Expanded: Commission E Monographs. Newton, MA: Integrative Medicine Communications, 2000.
9.
MarraJ. The State of Dietary Supplements. Harleysville, PA: The Natural Marketing Institute, 2002.
10.
BlumenthalM, BusseWR. The Complete German Commission E Monographs. Austin: American Botanical Council, 1998.
11.
BahrkeMS, MorganWR. Evaluation of the ergogenic properties of ginseng: an update. Sports Med29: 113–133, 2000.
12.
ChanRY, ChenWF, DongA, GuoD, WongMS. Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng.J Clin Endocrinol Metab87:3691–3695, 2002.
13.
DeanC. Menopause Naturally: A wide range of natural therapies to help women through this challenging passage. New Caanan: Keats Publishing, 1995.
14.
LuceroMA, McCloskeyWW. Alternatives to estrogen for the treatment of hot flashes. Ann Pharmacother31: 915–917, 1997.
15.
UtianWH. Current perspectives in the management of the menopausal and postmenopausal patient: introduction. Obstet Gynecol75: 1S–2S, 1990.
16.
ThompsonGA. Botanical characteristics of ginseng. In: CrakerLE, SimonJE, Eds. Herbs, Spices and Medicinal Plants: Recent advances in botany, horticulture, and pharmacology. Phoenix: Oryx Press, 1987.
17.
VuksanV, SievenpiperJL, KooVY, FrancisT, Beljan-ZdravkovicU, XuZ, VidgenE. American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med160: 1009–1013, 2000.
18.
VuksanV, StavroMP, SievenpiperJL, Beljan-ZdravkovicU, LeiterLA, JosseRG, XuZ. Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. Diabetes Care23: 1221–1226, 2000.
19.
ChungE, LeeKY, LeeYJ, LeeYH, LeeSK. Ginsenoside Rgl down-regulates glucocorticoid receptor and displays synergistic effects with cAMP. Steroids63: 421–424, 1998.
20.
LeeYJ, ChungE, LeeKY, LeeYH, HuhB, LeeSK. Ginsenoside-Rg1, one of the major active molecules from Panax ginseng, is a functional ligand of glucocorticoid receptor. Mol Cell Endocrinol133: 135–140, 1997.
21.
PearcePT, ZoisI, WynneKN, FunderJW. Panax ginseng and Eleuthrococcus senticosus extracts–in vitro studies on binding to steroid receptors. Endocrinol Jpn29: 567–573, 1982.
22.
SalvatiG, GenovesiG, MarcelliniL, PaoliniP, DeNI, PepeM, ReM. Effects of Panax ginseng C.A. Meyer saponins on male fertility. Panminerva Med38: 249–254, 1996.
23.
DudaRB, TabackB, KesselB, DooleyDD, YangH, MarchioriJ, SlomovicBM, AlvarezJG. pS2 expression induced by American ginseng in MCF-7 breast cancer cells. Ann Surg Oncol3: 515–520, 1996.
24.
AmatoP, ChristopheS, MellonPL. Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause9: 145–150, 2002.
25.
GreenspanEM. Ginseng and vaginal bleeding. JAMA249: 2018, 1983.
26.
HopkinsMP, AndroffL, BenninghoffAS. Ginseng face cream and unexplained vaginal bleeding. Am J Obstet Gynecol159: 1121–1122, 1988.
27.
PalmerBV, MontgomeryAC, MonteiroJC. Gin Seng and mastalgia. BMJ1: 1284, 1978.
28.
PunnonenR, LukolaA. Oestrogen-like effect of ginseng. BMJ281: 1110, 1980.
29.
PalopV, CatalanC, RubioE, Martinez-MirI. Gynecomastia in a male and ginseng. Med Clin112: 758, 1999.
30.
OlsenM, PetterssonH, KiesslingKH. Reduction of zearalenone to zearalenol in female rat liver by 3 alpha-hydroxysteroid dehydrogenase. Acta Pharmacol Toxicol48: 157–161, 1981.
31.
UenoY, TashiroF. alpha-Zearalenol, a major hepatic metabolite in rats of zearalenone, an estrogenic mycotoxin of Fusarium species. J Biochem89: 563–571, 1981.
32.
Kuiper-GoodmanT, ScottPM, WatanabeH. Risk assessment of the mycotoxin zearalenone. Regul Toxicol Pharmacol7: 253–306, 1987.
33.
Le GuevelR, PakdelF. Assessment of oestrogenic potency of chemicals used as growth promoter by in-vitro methods. Hum Reprod16: 1030–1036, 2001.
34.
WannemacherRWJr, BrunnerDL, NeufeldHA. Toxicity of Trichothecenes and other related mycotoxins in laboratory animals. In: SmithJE, HendersonRS, Eds. Mycotoxins and Animal Foods. Boca Raton: CRC Press, 2000.
35.
ObournJD, KoszewskiNJ, NotidesAC. Hormone- and DNA-binding mechanisms of the recombinant human estrogen receptor. Biochemistry32: 6229–6236, 1993.
36.
NashSM, SnyderWC. Quantitative estimations by plate counts of propagules of the bean rot Fusarium in field soils. Phytopathology52: 567–572, 1962.
37.
WareGM, ZhaoY, KuanSS, CarmanAS. Preparative method for isolating alpha-zearalenol and zearalenone using extracting disk. J AOAC Int82: 90–94, 1999.
38.
ViscontiA, PascaleM. Determination of zearalenone in corn by means of immunoaffinity clean-up and high-performance liquid chromatography with fluorescence detection. J Chromatogr A815: 133–140, 1998.
39.
EisenbergDM, KesslerRC, Van RompayMI, KaptchukTJ, WilkeySA, AppelS, DavisRB. Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med135: 344–351, 2001.
NealR. Report by David M. Eisenberg, M.D., on complementary and alternative medicine in the United States: overview and patterns of use. J Altern Complement Med7: S19–S21, 2001.
42.
ReillyD. Comments on complementary and alternative medicine in Europe. J Altern Complement Med7: S23–S31, 2001.
43.
DudaRB, ZhongY, NavasV, LiMZ, ToyBR, AlavarezJG. American ginseng and breast cancer therapeutic agents synergistically inhibit MCF-7 breast cancer cell growth. J Surg Oncol72: 230–239, 1999.
44.
LiuJ, BurdetteJE, XuH, GuC, Van BreemenRB, BhatKP, BoothN, ConstantinouAI, PezzutoJM, FongHH, FarnsworthNR, BoltonJL. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem49: 2472–2479, 2001.
45.
FujimotoJ, SakaguchiH, AokiI, ToyokiH, KhatunS, TamayaT. Inhibitory effect of ginsenoside-Rb2 on invasiveness of uterine endometrial cancer cells to the basement membrane. Eur J Gynaecol Oncol22: 339–341, 2001.
46.
LeeSJ, KoWG, KimJH, SungJH, MoonCK, LeeBH. Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease. Biochem Pharmacol60: 677–685, 2000.
47.
OhM, ChoiYH, ChoiS, ChungH, KimK, KimSI, KimDK, KimND. Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. Int J Oncol14: 869–875, 1999.
48.
ShibataS. Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci16: S28–S37, 2001.
49.
YunTK. Panax ginseng-a non-organ-specific cancer preventive?Lancet Oncol2: 49–55, 2001.
50.
LeeYJ, JinYR, LimWC, ParkWK, ChoJY, JangS, LeeSK. Ginsenoside-Rb1 acts as a weak phytoestrogen in MCF-7 human breast cancer cells. Arch Pharm Res26: 58–63, 2003.
51.
AlexopoulosC. Association of Fusarium mycotoxicosis with failure in applying an induction of parturition program with PGF2alpha and oxytocin in sows. Theriogenology55: 1745–1757, 2001.
52.
ChangK, KurtzHJ, MirochaCJ. Effects of the mycotoxin zearalenone on swine reproduction. Am J Vet Res40: 1260–1267, 1979.
53.
DacastoM, RolandoP, NachtmannC, CeppaL, NebbiaC. Zearalenone mycotoxicosis in piglets suckling sows fed contaminated grain. Vet Hum Toxicol37: 359–361, 1995.
54.
EtienneM, JemmaliM. Effects of feeding corn infested by Fusarium to sows abstract. C R Seances Acad Sci D288: 779–782, 1979.
55.
EtienneM, JemmaliM. Effects of zearalenone (F2) on estrous activity and reproduction in gilts. J Anim Sci55: 1–10, 1982.
56.
HobsonW, BaileyJ, FullerGB. Hormone effects of zearalenone in nonhuman primates. J Toxicol Environ Health4: 43–57, 1977.
57.
MeyerK, UsleberE, MartlbauerE, BauerJ. Occurrence of zearalenone alpha- and beta-zearalenol in bile of breeding sows in relation to reproductive performance abstract. Berl Munch Tierarztl Wochenschr113: 374–379, 2000.
58.
MinerviniF, Dell'AquilaME, MaritatoF, MinoiaP, ViscontiA. Toxic effects of the mycotoxin zearalenone and its derivatives on in vitro maturation of bovine oocytes and 17 beta-estradiol levels in mural granulosa cell cultures. Toxicol In Vitro15: 489–495, 2001.
59.
AhamedS, FosterJS, BukovskyA, DiehlJA, WimalasenaJ. Removal of Cdk inhibitors through both sequestration and downregulation in zearalenone-treated MCF-7 breast cancer cells. Mol Carcinog34: 45–58, 2002.
60.
AhamedS, FosterJS, BukovskyA, WimalasenaJ. Signal transduction through the Ras/Erk pathway is essential for the mycoestrogen zearalenone-induced cell-cycle progression in MCF-7 cells. Mol Carcinog30: 88–98, 2001.
61.
WithanageGS, MurataH, KoyamaT, IshiwataI. Agonistic and antagonistic effects of zearalenone, an estrogenic mycotoxin, on SKN, HHUA, and HepG2 human cancer cell lines. Vet Hum Toxicol43: 6–10, 2001.
62.
TomaszewskiJ, MiturskiR, SemczukA, KotarskiJ, JakowickiJ. Tissue zearalenone concentration in normal, hyperplastic and neoplastic human endometrium (abstract). Ginekol Pol69: 363–366, 1998.
63.
SchoentalR. Precocious sexual development in Puerto Rico and oestrogenic mycotoxins (zearalenone). Lancet1: 537, 1983.
64.
BarrettJ. Mycotoxins: of molds and maladies. Environ Health Perspect108: A20–A23, 2000.
65.
BohmJ. The significance of the mycotoxins desoxynivalenol, zearalenone and ochratoxin A for agricultural domestic animals abstract. Arch Tierernahr42: 95–111, 1992.
